Sign inCreate account

Report workspace tools

NCT01652690COMPLETEDanonymous

Prospective Observational Study to Describe Characteristics and Management of Patients With Postmenopausal Osteoporosis Treated With Prolia® in Routine Clinical Practice

Sponsor

Source record

Amgen

Phase

Source record

Observational

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

Denosumab (Prolia®)

Indication / condition

AI-normalized

Osteoporosis, Postmenopausal

Intervention

Source record

Denosumab

Source & freshness

Source record

NCT ID

NCT01652690

Original source

ClinicalTrials.gov

Source last updated

Mar 06, 2019

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT01652690

Title

Prospective Observational Study to Describe Characteristics and Management of Patients With Postmenopausal Osteoporosis Treated With Prolia® in Routine Clinical Practice

Sponsor

Amgen

Status

COMPLETED

Phase

Observational

Condition raw

Osteoporosis, Postmenopausal

Condition normalized

Osteoporosis, Postmenopausal

Modality raw

Osteoporosis, Postmenopausal

Modality normalized

monoclonal antibody

Target raw

Denosumab (Prolia®)

Target normalized

Denosumab (Prolia®)

Interventions

Denosumab

Public preview

Source record

This study aimed to characterize the management of postmenopausal osteoporosis patients treated with denosumab in routine clinical practice across the Czech Republic and Slovakia. It involved 600 participants and focused on treatment adherence and safety data over a 24-month period.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Prospective Observational Study to Describe Characteristics and Management of Patients With Postmenopausal Osteoporosis Treated With Prolia® in Routine Clinical Practice

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT01652690

Status

COMPLETED

Phase

Observational

Sponsor

Amgen

Executive brief

Investment-Ready Snapshot

This study aimed to characterize the management of postmenopausal osteoporosis patients treated with denosumab in routine clinical practice across the Czech Republic and Slovakia. It involved 600 participants and focused on treatment adherence and safety data over a 24-month period.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedMar 06, 2019
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT01652690

Indication

Osteoporosis, Postmenopausal

Modality

monoclonal antibody

Target

Denosumab (Prolia®)

Intervention

Denosumab

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.